World's Best Scientists 2026 revealed!
James J. Vredenburgh

James J. Vredenburgh

D-Index & Metrics

Medicine

D-Index
78
Citations
25397
World Ranking
17944
National Ranking
8951

Overview

James J. Vredenburgh is affiliated with the Yale School of Medicine in the United States, focusing primarily on research within the field of Medicine. Their work spans several specialized subfields, including Pulmonary and Respiratory Medicine, Oncology, Genetics, Immunology, and Neurology.

The main research topics covered by James J. Vredenburgh include:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Lung Cancer Treatments and Mutations
  • Lymphoma Diagnosis and Treatment
  • Immunotherapy and Immune Responses
  • Sarcoma Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments

Recent publications by Vredenburgh reflect a focus on oncology and cancer treatment, with significant contributions to research on glioblastoma, lung cancer, lymphoma, and immune biomarkers in myeloma. Selected papers include:

  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma (2023, Journal of Clinical Oncology)
  • Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial (2020, Clinical Cancer Research)
  • Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments (2022, Clinical Cancer Research)
  • Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma (2022, Cancer Cell)
  • Primary Bone Lymphoma: A Case Series and Review of Literature (2020, Case Reports in Hematology)

Frequent co-authors collaborating with Vredenburgh include:

  • Nerea Lopetegui-Lia
  • David A. Reardon
  • Henry S. Friedman
  • Annick Desjardins
  • John H. Sampson

The preferred publication venues for Vredenburgh's contributions are diverse but show repeated appearances in:

  • Cureus
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Cell
  • Case Reports in Hematology

Best Publications

  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

    Henry S. Friedman;Michael D. Prados;Patrick Y. Wen;Tom Mikkelsen

  • Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello

  • Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jeannette M. Dowell

  • Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

    John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape

  • Phase II Trial of Gefitinib in Recurrent Glioblastoma

    Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell

  • High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

    W P Peters;M Ross;J J Vredenburgh;B Meisenberg

  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

    Duane A. Mitchell;Kristen A. Batich;Michael D. Gunn;Min-Nung Huang

  • Molecularly targeted therapy for malignant glioma

    Sith Sathornsumetee;David A. Reardon;Annick Desjardins;Jennifer A. Quinn

  • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

    Paul G Richardson;Carol Murakami;Zhezhen Jin;Diane L Warren

  • Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.

    William P. Peters;Gary Rosner;Maureen Ross;James Vredenburgh

  • Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme

    David A. Reardon;Merrill J. Egorin;Jennifer A. Quinn;Jeremy N. Rich

  • Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

    John H. Sampson;Kenneth D. Aldape;Kenneth D. Aldape;Gary E. Archer;April Coan

  • Treatment of Severe Veno-Occlusive Disease With Defibrotide: Compassionate Use Results in Response Without Significant Toxicity in a High-Risk Population

    Paul G. Richardson;Anthony D. Elias;Amrita Krishnan;Catherine Wheeler

  • Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

    Sith Sathornsumetee;Yiting Cao;Jennifer E. Marcello;James E. Herndon

  • Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

    Jennifer A. Quinn;Sara Xiaoyin Jiang;David A. Reardon;Annick Desjardins

  • Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

    David A. Reardon;Annick Desjardins;James J. Vredenburgh;Sridharan Gururangan

  • Liver metastases from breast cancer: Long-term survival after curative resection

    Markus Selzner;Michael A. Morse;James J. Vredenburgh;William C. Meyers

  • Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

    Jennifer A. Quinn;Annick Desjardins;Jon David Weingart;Henry Brem

  • Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

    David A. Reardon;Gamal Akabani;R. Edward Coleman;Allan H. Friedman

  • Neurofibromatosis type 2

    S. Sathornsumetee;A. DesJardins;D. A. Reardon;J. N. Rich

Frequent Co-Authors

David A. Reardon
David A. Reardon Harvard University
Henry S. Friedman
Henry S. Friedman Duke University
James E. Herndon
James E. Herndon Duke University
John H. Sampson
John H. Sampson Duke University
Allan H. Friedman
Allan H. Friedman Duke University
Jeremy N. Rich
Jeremy N. Rich University of Pittsburgh
Roger E. McLendon
Roger E. McLendon Duke University
Darell D. Bigner
Darell D. Bigner Duke University
Nelson J. Chao
Nelson J. Chao Duke University
Patrick Y. Wen
Patrick Y. Wen Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While traditional medical school remains a common route, a growing number of healthcare professionals are choosing flexible online programs. If you’re considering advanced roles in medicine, nursing, or healthcare technology, online degrees open up a range of possibilities.

For those looking to become nurse practitioners or leaders in nursing, best online dnp programs can help you earn a Doctor of Nursing Practice with the flexibility of virtual study. Aspiring pharmacists can now explore pharm d online programs, allowing students to prepare for rewarding pharmacy careers without relocating.

Not every healthcare career requires patient care. If you are interested in data, technology, or organization, health information technology programs online provide a clear path into hospital administration, medical record management, and data security.

Additionally, there’s growing need for specialized roles like medical billers and coders. Many pursue certification through affordable online courses; you can learn more about medical coding certification cost to see if this career fits your goals.

Best Scientists Citing James J. Vredenburgh

Trending Scientists

Recently Published Articles